PL3096786T3 - Polisacharydy otoczkowe streptococcus pneumoniae i ich koniugaty - Google Patents

Polisacharydy otoczkowe streptococcus pneumoniae i ich koniugaty

Info

Publication number
PL3096786T3
PL3096786T3 PL15708581T PL15708581T PL3096786T3 PL 3096786 T3 PL3096786 T3 PL 3096786T3 PL 15708581 T PL15708581 T PL 15708581T PL 15708581 T PL15708581 T PL 15708581T PL 3096786 T3 PL3096786 T3 PL 3096786T3
Authority
PL
Poland
Prior art keywords
conjugates
streptococcus pneumoniae
capsular polysaccharides
pneumoniae capsular
polysaccharides
Prior art date
Application number
PL15708581T
Other languages
English (en)
Inventor
Mingming Han
Avvari Krishna PRASAD
David Cooper
Wendy Jo Watson
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52630421&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3096786(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of PL3096786T3 publication Critical patent/PL3096786T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0003—General processes for their isolation or fractionation, e.g. purification or extraction from biomass
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/04—Polysaccharides, i.e. compounds containing more than five saccharide radicals attached to each other by glycosidic bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Materials Engineering (AREA)
  • Biotechnology (AREA)
  • Polymers & Plastics (AREA)
  • Sustainable Development (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL15708581T 2014-01-21 2015-01-15 Polisacharydy otoczkowe streptococcus pneumoniae i ich koniugaty PL3096786T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461929561P 2014-01-21 2014-01-21
EP15708581.2A EP3096786B1 (en) 2014-01-21 2015-01-15 Streptococcus pneumoniae capsular polysaccharides and conjugates thereof
PCT/IB2015/050316 WO2015110942A2 (en) 2014-01-21 2015-01-15 Streptococcus pneumoniae capsular polysaccharides and conjugates thereof

Publications (1)

Publication Number Publication Date
PL3096786T3 true PL3096786T3 (pl) 2021-11-08

Family

ID=52630421

Family Applications (2)

Application Number Title Priority Date Filing Date
PL19179577.2T PL3583947T3 (pl) 2014-01-21 2015-01-15 Polisacharydy otoczkowe streptococcus pneumoniae i ich koniugaty
PL15708581T PL3096786T3 (pl) 2014-01-21 2015-01-15 Polisacharydy otoczkowe streptococcus pneumoniae i ich koniugaty

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL19179577.2T PL3583947T3 (pl) 2014-01-21 2015-01-15 Polisacharydy otoczkowe streptococcus pneumoniae i ich koniugaty

Country Status (22)

Country Link
US (3) US20160324949A1 (pl)
EP (3) EP3096786B1 (pl)
JP (3) JP6585624B2 (pl)
KR (4) KR102619514B1 (pl)
CN (3) CN120131934A (pl)
AU (3) AU2015208822B2 (pl)
BR (2) BR122023022294A2 (pl)
CA (1) CA2937190A1 (pl)
DK (2) DK3096786T3 (pl)
ES (2) ES2883571T3 (pl)
FI (1) FI3583947T3 (pl)
FR (1) FR22C1041I2 (pl)
HK (1) HK1232133A1 (pl)
HR (2) HRP20211288T1 (pl)
HU (2) HUE055553T2 (pl)
IL (2) IL311385A (pl)
MX (2) MX386692B (pl)
PL (2) PL3583947T3 (pl)
PT (2) PT3096786T (pl)
RU (2) RU2688831C2 (pl)
SI (2) SI3096786T1 (pl)
WO (1) WO2015110942A2 (pl)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2883343T3 (es) 2014-01-21 2021-12-07 Pfizer Polisacáridos capsulares de Streptococcus pneumoniae y conjugados de los mismos
US11160855B2 (en) 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
TWI807252B (zh) * 2015-05-04 2023-07-01 美商輝瑞股份有限公司 Ｂ型鏈球菌多醣-蛋白質軛合物、製造軛合物之方法、含軛合物之免疫原性組成物、及其用途
TWI756893B (zh) * 2015-07-21 2022-03-01 美商輝瑞股份有限公司 包含經共軛之莢膜糖抗原的致免疫性組成物、包含該致免疫性組成物之套組及彼等之用途
CN109862908B (zh) 2016-08-05 2023-05-02 圣诺菲·帕斯图尔公司 多价肺炎球菌多糖-蛋白质缀合物组合物
IL264553B2 (en) 2016-08-05 2023-04-01 Sanofi Pasteur Inc A multivalent pneumococcal protein-polysaccharide conjugate preparation
EP4467565A3 (en) 2016-12-21 2025-03-12 Amgen Inc. Anti-tnf alpha antibody formulations
WO2018124959A2 (en) 2016-12-28 2018-07-05 Henriques Normark Birgitta Microparticles from streptococcus pneumoniae as vaccine antigens
US11951165B2 (en) 2016-12-30 2024-04-09 Vaxcyte, Inc. Conjugated vaccine carrier proteins
CN118662649A (zh) 2016-12-30 2024-09-20 Vaxcyte公司 具有非天然氨基酸的多肽-抗原缀合物
HUE059252T2 (hu) * 2017-01-20 2022-11-28 Pfizer Immunogén készítmények pneumokokkusz vakcinákban történõ alkalmazásra
CN116870144A (zh) 2017-01-31 2023-10-13 默沙东有限责任公司 制备多糖-蛋白缀合物的方法
CA3052621A1 (en) 2017-02-03 2018-08-09 Schadeck, Eva Barbara Haemophilus influenzae saccharide-carrier conjugate compositions and uses thereof
CN110337307A (zh) 2017-02-24 2019-10-15 默沙东公司 增强肺炎链球菌多糖-蛋白缀合物的免疫原性
WO2018222741A1 (en) * 2017-05-31 2018-12-06 Oklahoma Medical Research Foundation Bispecific antibodies for the treatment of streptococcus pneumonia
US10729763B2 (en) 2017-06-10 2020-08-04 Inventprise, Llc Mixtures of polysaccharide-protein pegylated compounds
CN118356485A (zh) 2017-06-10 2024-07-19 创赏公司 提供改善的免疫原性和亲合力的具有二价或多价缀合物多糖的多价缀合物疫苗
WO2019043245A1 (en) * 2017-09-04 2019-03-07 London School Of Hygiene And Tropical Medicine MICROBIAL CELLS EXPRESSING STREPTOCOCCAL SERROTYPES
CN111065387B (zh) 2017-09-07 2023-08-25 默沙东有限责任公司 肺炎球菌多糖及其在免疫原性多糖-载体蛋白缀合物中的用途
KR102734995B1 (ko) 2017-09-07 2024-11-26 머크 샤프 앤드 돔 엘엘씨 폐렴구균 폴리사카라이드 및 면역원성 폴리사카라이드-담체 단백질 접합체에서의 그의 용도
US12257295B2 (en) 2017-10-04 2025-03-25 Pogona, LLC Saccharide-polypeptide conjugate compositions and methods of use thereof
EA202091382A1 (ru) 2017-12-06 2021-01-15 Мерк Шарп И Доум Корп. Композиции, содержащие конъюгаты полисахарид streptococcus pneumoniae с белком, и способы их применения
IL276230B2 (en) 2018-02-05 2024-01-01 Sanofi Pasteur Inc Multivalent pneumococcal polysaccharide-protein conjugate composition
CN111757754B (zh) 2018-02-05 2024-07-05 赛诺菲巴斯德有限公司 多价肺炎球菌多糖-蛋白质缀合物组合物
KR20190121713A (ko) 2018-04-18 2019-10-28 에스케이바이오사이언스(주) 스트렙토코커스 뉴모니애 협막 다당류 및 그의 면역원성 접합체
EP3787674A4 (en) 2018-04-30 2022-01-26 Merck Sharp & Dohme Corp. PROCESS FOR THE PRODUCTION OF STREPTOCOCCUS PNEUMONIAE POLYSACCHARIDE CAPSULAR PROTEIN CONJUGATES FROM LYOSPHERES
JP7506605B6 (ja) * 2018-04-30 2024-07-16 メルク・シャープ・アンド・ドーム・エルエルシー 肺炎球菌莢膜多糖類担体タンパク質複合体の製造方法
EP3788143B1 (en) 2018-04-30 2023-06-28 Merck Sharp & Dohme LLC Methods for providing a homogenous solution of lyophilized mutant diptheria toxin in dimethylsulfoxide
AU2019299836B2 (en) * 2018-07-04 2025-08-21 Vaxcyte, Inc. Improvements in immunogenic conjugates
US12048739B2 (en) * 2018-09-23 2024-07-30 Biological E Limited Purified capsular polysaccharides of Streptococcus pneumoniae
GEP20247633B (en) * 2018-12-19 2024-06-25 Merck Sharp & Dohme Llc Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof
JP7239509B6 (ja) 2019-02-22 2023-03-28 ファイザー・インク 細菌多糖類を精製するための方法
TWI864052B (zh) * 2019-07-18 2024-12-01 南韓商賽特瑞恩股份有限公司 包含多價肺炎球菌多醣-蛋白共軛物的免疫組成物、醫藥組成物及其用途
EP4003410A1 (en) * 2019-07-31 2022-06-01 Sanofi Pasteur, Inc. Multivalent pneumococcal polysaccharide-protein conjugate compositions and methods of using the same
CN113493790A (zh) * 2020-04-01 2021-10-12 南京华普生物技术股份有限公司 具有免疫调节功能的CpG ODN及其应用
WO2021229604A1 (en) * 2020-05-14 2021-11-18 Serum Institute Of India Private Limited Methods for simultaneous fragmentation and purification of bacterial polysaccharides
WO2022035816A1 (en) 2020-08-10 2022-02-17 Inventprise, Llc Multivalent pneumococcal glycoconjugate vaccines containing emerging serotype 24f
WO2022097010A1 (en) 2020-11-04 2022-05-12 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
CN113607939B (zh) * 2021-08-05 2024-10-22 艾美探索者生命科学研发有限公司 肺炎球菌多糖结合疫苗各型结合原液吸附率测定方法

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4686102A (en) * 1984-04-12 1987-08-11 American Cyanamid Company Multivalent pneumococcal vaccine and preparation thereof
US4709017A (en) 1985-06-07 1987-11-24 President And Fellows Of Harvard College Modified toxic vaccines
US4950740A (en) 1987-03-17 1990-08-21 Cetus Corporation Recombinant diphtheria vaccines
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
DE3841091A1 (de) 1988-12-07 1990-06-13 Behringwerke Ag Synthetische antigene, verfahren zu ihrer herstellung und ihre verwendung
ES2055785T3 (es) 1989-01-17 1994-09-01 Eniricerche Spa Peptidos sinteticos y su uso como vehiculos universales para la preparacion de conjugados inmunogenos aptos para el desarrollo de vacunas sinteticas.
JPH0832638B2 (ja) 1989-05-25 1996-03-29 カイロン コーポレイション サブミクロン油滴乳剤を含んで成るアジュバント製剤
EP0482068A1 (en) 1989-07-14 1992-04-29 American Cyanamid Company Cytokine and hormone carriers for conjugate vaccines
IT1237764B (it) 1989-11-10 1993-06-17 Eniricerche Spa Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici.
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
IL98715A0 (en) 1990-08-13 1992-07-15 American Cyanamid Co Filamentous hemaglutinin of bodetella pertussis as a carrier molecule for conjugate vaccines
US5153312A (en) * 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
CA2059693C (en) * 1991-01-28 2003-08-19 Peter J. Kniskern Polysaccharide antigens from streptococcus pneumoniae
CA2059692C (en) * 1991-01-28 2004-11-16 Peter J. Kniskern Pneumoccoccal polysaccharide conjugate vaccine
IL101715A (en) 1991-05-02 2005-06-19 Amgen Inc Recombinant dna-derived cholera toxin subunit analogs
JPH07507854A (ja) 1991-12-23 1995-08-31 ツォッヒェ，ミヒャエル 油除去装置を備えたエンジン
AU685047B2 (en) 1992-02-11 1998-01-15 Henry M. Jackson Foundation For The Advancement Of Military Medicine Dual carrier immunogenic construct
IT1262896B (it) 1992-03-06 1996-07-22 Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini.
WO1993021769A1 (en) 1992-05-06 1993-11-11 President And Fellows Of Harvard College Diphtheria toxin receptor-binding region
IL102687A (en) 1992-07-30 1997-06-10 Yeda Res & Dev Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them
ES2231770T3 (es) 1993-03-05 2005-05-16 Wyeth Holdings Corporation Nuevos plasmidos para la produccion de proteina crm y toxina difterica.
KR100376361B1 (ko) 1993-09-22 2003-07-18 헨리 엠. 잭슨 파운데이션 포 더 어드벤스먼트 오브 밀리터리 메디신 면역원성구조체의제조를위하여신규한시아닐레이팅시약을사용하여용해성탄수화물을활성화하는방법
US5917017A (en) 1994-06-08 1999-06-29 President And Fellows Of Harvard College Diphtheria toxin vaccines bearing a mutated R domain
US6455673B1 (en) 1994-06-08 2002-09-24 President And Fellows Of Harvard College Multi-mutant diphtheria toxin vaccines
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
PT772619E (pt) 1994-07-15 2006-10-31 Univ Iowa Res Found Oligonucleotidos imunomoduladores
CA2215933C (en) 1995-03-22 2009-10-13 Andrew Lees Producing immunogenic constructs using soluble carbohydrates activated via organic cyanylating reagents
US5714354A (en) * 1995-06-06 1998-02-03 American Home Products Corporation Alcohol-free pneumococcal polysaccharide purification process
CA2281838A1 (en) 1997-02-28 1998-09-03 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated cpg dinucleotide in the treatment of lps-associated disorders
US6299881B1 (en) 1997-03-24 2001-10-09 Henry M. Jackson Foundation For The Advancement Of Military Medicine Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
ATE370740T1 (de) 1997-05-20 2007-09-15 Ottawa Health Research Inst Verfahren zur herstellung von nukleinsäurekonstrukten
GB9713156D0 (en) 1997-06-20 1997-08-27 Microbiological Res Authority Vaccines
DE69935507T2 (de) 1998-04-03 2007-12-06 University Of Iowa Research Foundation Verfahren und produkte zur stimulierung des immunsystems mittels immunotherapeutischer oligonukleotide und zytokine
WO2000018434A1 (en) 1998-09-30 2000-04-06 American Cyanamid Company Mutant cholera holotoxin as an adjuvant
US6582706B1 (en) 1998-12-21 2003-06-24 Medimmune, Inc. Vaccine compositions comprising Streptococcus pneumoniae polypeptides having selected structural MOTIFS
MXPA01006427A (es) 1998-12-23 2002-06-04 Shire Biochem Inc Nuevos antigenos de estreptococos.
US6936258B1 (en) 1999-03-19 2005-08-30 Nabi Biopharmaceuticals Staphylococcus antigen and vaccine
WO2000061761A2 (en) 1999-04-09 2000-10-19 Techlab, Inc. Recombinant clostridium toxin a protein carrier for polysaccharide conjugate vaccines
GB0007432D0 (en) 2000-03-27 2000-05-17 Microbiological Res Authority Proteins for use as carriers in conjugate vaccines
PL214229B1 (pl) 2000-06-20 2013-07-31 Id Biomedical Corp Wyizolowany polipeptyd przeciwko paciorkowcom, sposób jego wytwarzania i zastosowanie
US20030035806A1 (en) 2001-05-11 2003-02-20 D'ambra Anello J. Novel meningitis conjugate vaccine
KR100877258B1 (ko) 2001-06-07 2009-01-12 와이어쓰 홀딩스 코포레이션 보조제로서 콜레라 홀로톡신의 돌연변이체 형태
WO2002098368A2 (en) 2001-06-07 2002-12-12 Wyeth Holdings Corporation Mutant forms of cholera holotoxin as an adjuvant
EP1425040A2 (en) 2001-09-14 2004-06-09 Cytos Biotechnology AG In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles
US7262024B2 (en) 2001-12-20 2007-08-28 Id Biomedical Corporation Streptococcus antigens
CA2812817C (en) 2003-03-13 2016-12-20 Glaxosmithkline Biologicals S.A. Method of detoxification of pneumolysin
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
WO2007026190A2 (en) 2004-07-18 2007-03-08 Csl Limited Immuno stimulating complex and oligonucleotide formulations for inducing enhanced interferon-gamma responses
US7955605B2 (en) * 2005-04-08 2011-06-07 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
US7709001B2 (en) 2005-04-08 2010-05-04 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
KR102564388B1 (ko) 2005-04-08 2023-08-08 와이어쓰 엘엘씨 다가 폐렴구균 다당류-단백질 접합체 조성물
US20070184072A1 (en) 2005-04-08 2007-08-09 Wyeth Multivalent pneumococcal polysaccharide-protein conjugate composition
MX2007012337A (es) 2005-04-08 2007-11-21 Wyeth Corp Separacion de contaminantes de polisacarido de streptococcus pneumoniae por manipulacion de ph.
TR201900418T4 (tr) * 2005-12-22 2019-02-21 Glaxosmithkline Biologicals Sa Pnömokok polisakkarit konjugat aşısı.
DE602007007642D1 (de) 2006-10-10 2010-08-19 Wyeth Llc Verbesserte verfahren zur trennung von streptococcus pneumoniae-3-polysacchariden
HUE059085T2 (hu) 2007-03-23 2022-10-28 Wyeth Llc Streptococcus pneumoniae tokpoliszacharidok elõállítására szolgáló rövidített tisztítási eljárás
ES2621359T3 (es) * 2007-06-20 2017-07-03 Pfizer Ireland Pharmaceuticals Polisacáridos modificados para vacunas conjugadas
EA020817B1 (ru) 2007-06-26 2015-02-27 Глаксосмитклайн Байолоджикалс С.А. Вакцина, содержащая конъюгаты капсульных полисахаридов streptococcus pneumoniae
CA2757620C (en) 2009-04-30 2016-04-26 Coley Pharmaceutical Group, Inc. Pneumococcal vaccine and uses thereof
NZ597191A (en) * 2009-06-22 2013-11-29 Wyeth Llc Compositions and methods for preparing staphylococcus aureus serotype 5 and 8 capsular polysaccharide conjugate immunogenic compositions
TW201136603A (en) 2010-02-09 2011-11-01 Merck Sharp & Amp Dohme Corp 15-valent pneumococcal polysaccharide-protein conjugate vaccine composition
GB201003922D0 (en) * 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Conjugation process
JP2014502595A (ja) * 2010-12-10 2014-02-03 メルク・シャープ・アンド・ドーム・コーポレーション 免疫原性組成物の撹拌誘導凝集を緩和する新規な製剤
GB201103836D0 (en) * 2011-03-07 2011-04-20 Glaxosmithkline Biolog Sa Conjugation process
AU2012255878B2 (en) * 2011-05-18 2016-05-12 Matrivax Research & Development Corporation Protein matrix vaccine compositions including polycations
KR102057217B1 (ko) * 2012-06-20 2020-01-22 에스케이바이오사이언스 주식회사 다가 폐렴구균 다당류-단백질 접합체 조성물
KR101742406B1 (ko) * 2012-08-16 2017-05-31 화이자 인코포레이티드 당접합 공정 및 조성물
CA2943263C (en) * 2012-12-20 2018-12-04 Pfizer Inc. Glycoconjugation process
ITMI20130142A1 (it) 2013-01-31 2014-08-01 Biosynth Srl Vaccini glicoconiugati comprendenti unita' di base di un costrutto molecolare esprimente epitopi multipli incorporati
IL296681B2 (en) * 2014-01-21 2024-09-01 Pfizer Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
TWI756893B (zh) * 2015-07-21 2022-03-01 美商輝瑞股份有限公司 包含經共軛之莢膜糖抗原的致免疫性組成物、包含該致免疫性組成物之套組及彼等之用途

Also Published As

Publication number Publication date
KR102229568B1 (ko) 2021-03-18
FR22C1041I1 (fr) 2022-09-09
WO2015110942A3 (en) 2015-11-26
AU2023201579B2 (en) 2025-04-03
CN112336854B (zh) 2024-11-26
CN112336854A (zh) 2021-02-09
US20160324949A1 (en) 2016-11-10
DK3096786T3 (da) 2021-08-02
US20210121555A1 (en) 2021-04-29
KR20220156982A (ko) 2022-11-28
CN120131934A (zh) 2025-06-13
EP3583947B1 (en) 2023-10-11
IL246738B2 (en) 2024-08-01
SI3096786T1 (sl) 2021-09-30
KR20210032013A (ko) 2021-03-23
HRP20231504T1 (hr) 2024-03-01
RU2743793C1 (ru) 2021-02-26
HUE055553T2 (hu) 2021-12-28
IL311385A (en) 2024-05-01
AU2015208822A1 (en) 2016-07-21
FI3583947T3 (fi) 2023-10-12
HUE064837T2 (hu) 2024-05-28
HRP20211288T1 (hr) 2021-11-26
RU2016127123A3 (pl) 2018-02-28
ES2883571T3 (es) 2021-12-09
PL3583947T3 (pl) 2024-04-02
IL246738A0 (en) 2016-08-31
MX2020001138A (es) 2021-09-30
AU2023201579A1 (en) 2023-04-13
JP2021105036A (ja) 2021-07-26
AU2015208822B2 (en) 2020-06-18
DK3583947T3 (da) 2023-11-06
CN106413747A (zh) 2017-02-15
AU2020204508A1 (en) 2020-07-23
CA2937190A1 (en) 2015-07-30
HK1232133A1 (zh) 2018-01-05
EP3096786B1 (en) 2021-07-07
PT3096786T (pt) 2021-08-24
JP2017504661A (ja) 2017-02-09
EP3583947A1 (en) 2019-12-25
KR102619514B1 (ko) 2023-12-28
JP7216137B2 (ja) 2023-01-31
FR22C1041I2 (fr) 2023-05-26
JP2019172701A (ja) 2019-10-10
EP4286000A3 (en) 2024-02-14
AU2020204508B2 (en) 2023-02-02
PT3583947T (pt) 2023-12-14
BR112016016580A2 (pt) 2017-10-03
US20190070283A1 (en) 2019-03-07
ES2965616T3 (es) 2024-04-16
KR20190133066A (ko) 2019-11-29
EP4286000A2 (en) 2023-12-06
SI3583947T1 (sl) 2024-01-31
KR102049825B1 (ko) 2019-12-03
MX371453B (es) 2020-01-29
KR20160104076A (ko) 2016-09-02
IL246738B1 (en) 2024-04-01
MX386692B (es) 2025-03-19
BR112016016580B1 (pt) 2024-01-09
EP3096786A2 (en) 2016-11-30
MX2016009469A (es) 2016-10-13
BR122023022294A2 (pt) 2023-12-12
RU2016127123A (ru) 2018-02-28
JP6585624B2 (ja) 2019-10-02
WO2015110942A2 (en) 2015-07-30
RU2688831C2 (ru) 2019-05-22

Similar Documents

Publication Publication Date Title
IL283554A (en) Capsular polysaccharides of Streptococcus pneumoniae and their conjugates
FR22C1041I2 (fr) Polysaccharides capsulaires de streptococcus pneumoniae et leurs conjugués
IL290457A (en) Antibodies and their conjugates
IL258248A (en) Attraction Oligonucleotide Conjugates and Their Uses
IL248961A0 (en) Oristatin histories and their conjugations
SMT202400223T1 (it) Coniugati comprendenti gruppi autoimmolativi e metodi correlati ad essi
IL265471A (en) Pulling-oligonucleotide conjugates and their uses
IL247344A0 (en) A new polysaccharide and its uses
ZA201701337B (en) Conjugates and conjugating reagents
IL258759A (en) Anti-cd3-folate conjugates and their uses
ZA201608327B (en) Curcumin-peptide conjugates and formulations thereof
PT3544637T (pt) Conjugados omv-antigénio nativos e sua utilização
HK40126663A (zh) 肺炎链球菌荚膜多糖及其缀合物
GB201818562D0 (en) Pyrrolobenzodiazephones and conjugates thereof
GB201418986D0 (en) Novel conjugates and novel conjugating reagents